Division of Haematology/Oncology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, 555 University Ave, Toronto, ON M5G 1X8, Canada.
Division of Nuclear Medicine, Department of Diagnostic Imaging, The Hospital for Sick Children, University of Toronto, 555 University Ave, Toronto, ON M5G 1X8, Canada.
PET Clin. 2021 Jul;16(3):419-427. doi: 10.1016/j.cpet.2021.03.006.
Theranostics combines diagnosis and targeted therapy, achieved by the use of the same or similar molecules labeled with different radiopharmaceuticals or identical with different dosages. One of the best examples is the use of metaiodobenzylguanidine (MIBG). In the management of neuroblastoma-the most common extracranial solid tumor in children. MIBG has utility not only for diagnosis, risk-stratification, and response monitoring but also for cancer therapy, particularly in the setting of relapsed/refractory disease. Improved techniques and new emerging radiopharmaceuticals likely will strengthen the role of nuclear medicine in the management of neuroblastoma.
治疗学结合了诊断和靶向治疗，通过使用相同或相似的分子标记不同的放射性药物或相同的分子但剂量不同来实现。最好的例子之一是使用间碘苄胍（MIBG）。在神经母细胞瘤的治疗中——儿童最常见的颅外实体瘤。MIBG 不仅在诊断、风险分层和反应监测方面有应用，而且在癌症治疗方面也有应用，特别是在复发/难治性疾病的情况下。改进的技术和新出现的放射性药物可能会加强核医学在神经母细胞瘤治疗中的作用。
